Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite

The effects of single doses of intravenous (IV) ciprofloxacin and rifampin and of multiple doses of rifampin on glyburide exposure and blood glucose levels were investigated in nine healthy volunteers. A single IV dose of rifampin significantly increased the area under the concentration–time curve (AUC) of glyburide and its metabolite. Blood glucose levels were significantly lower than those observed after dosing with glyburide alone. Multiple doses of rifampin induced an increase in liver enzyme levels, leading to a marked decrease in glyburide exposure and blood glucose levels. When IV rifampin was administered after multiple doses of rifampin, the inhibition of hepatic uptake transporters masked the induction effect; however, the relative changes in AUC for glyburide and its hydroxyl metabolite were similar to those seen under noninduced conditions. The studies reported here demonstrate how measurements of the levels of both the parent drug and its primary metabolite are useful in unmasking simultaneous drug–drug induction and inhibition effects and in characterizing enzymatic vs. transporter mechanisms.

[1]  J. Feldman,et al.  Glyburide: A Second‐generation Sulfonylurea Hypoglycemic Agent , 1985, Pharmacotherapy.

[2]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[3]  T. Self,et al.  Interaction of rifampin and glyburide. , 1989, Chest.

[4]  J. Kolars,et al.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.

[5]  M. Relling,et al.  P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Surekha,et al.  Drug interaction: rifampicin and glibenclamide. , 1997, The National medical journal of India.

[7]  H. Yawo,et al.  Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1* , 1999, The Journal of Biological Chemistry.

[8]  B. Masereel,et al.  P-glycoprotein inhibition by glibenclamide and related compounds , 1999, Pflügers Archiv.

[9]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[10]  M. Fromm,et al.  The effect of rifampin treatment on intestinal expression of human MRP transporters. , 2000, The American journal of pathology.

[11]  D. Keppler,et al.  A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[12]  D. Keppler,et al.  Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide* , 2000, The Journal of Biological Chemistry.

[13]  P. Neuvonen,et al.  Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide , 2001, Clinical pharmacology and therapeutics.

[14]  S. Vavricka,et al.  Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver , 2002, Hepatology.

[15]  P. Neuvonen,et al.  Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes , 2002, Clinical pharmacology and therapeutics.

[16]  Wolfgang Rohde,et al.  Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers , 2002, Clinical pharmacology and therapeutics.

[17]  R. Kim,et al.  Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[18]  Leslie Z Benet,et al.  Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[19]  Yuichi Sugiyama,et al.  Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.

[20]  L. Spillane,et al.  Refractory Hypoglycemia from Ciprofloxacin and Glyburide Interaction , 2004, Journal of toxicology. Clinical toxicology.

[21]  Leslie Z. Benet,et al.  Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay , 2004, Journal of Pharmacology and Experimental Therapeutics.

[22]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[23]  Hong Sun,et al.  EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN , 2004, Drug Metabolism and Disposition.

[24]  L. Benet,et al.  Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[25]  K. Brøsen,et al.  Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide , 2004, European Journal of Clinical Pharmacology.

[26]  Y. Sawada,et al.  CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B , 2005, Drug Metabolism and Disposition.

[27]  U. Christians,et al.  Cyclosporine Pharmacokinetics and Dosing Modifications in Human Immunodeficiency Virus-Infected Liver and Kidney Transplant Recipients , 2005, Transplantation.

[28]  O. Kohlbacher,et al.  Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3). , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[29]  L. Benet,et al.  Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and Metabolism , 2006, Journal of Pharmacology and Experimental Therapeutics.

[30]  Leslie Z. Benet,et al.  PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM , 2006, Drug Metabolism and Disposition.

[31]  L. Benet,et al.  Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[32]  A. Treiber,et al.  Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects , 2007, Clinical pharmacology and therapeutics.

[33]  C. Schäfer,et al.  Clinical relevance. , 2010, Deutsches Arzteblatt international.